cellular
humor
immun
respons
dog
candid
vaccin
compos
leishmania
braziliensi
promastigot
protein
plu
saponin
adjuv
investig
prerequisit
understand
mechan
immunogen
canin
viscer
leishmaniasi
cvl
candid
vaccin
elicit
strong
antigen
relat
increas
antileishmania
igg
isotyp
togeth
higher
level
lymphocyt
particularli
circul
tlymphocyt
leishmania
chagasi
antigenspecif
tlymphocyt
indic
intens
cell
prolifer
increas
nitric
oxid
product
vitro
stimul
l
chagasi
solubl
antigen
candid
vaccin
elicit
immun
activ
statu
potenti
compat
effect
control
etiolog
agent
cvl
canin
viscer
leishmaniasi
cvl
caus
leishmania
l
chagasi
syn
leishmania
l
infantum
repres
major
veterinari
public
health
problem
variou
region
new
world
countri
around
mediterranean
basin
endem
area
brazil
preval
cvl
reportedli
rang
dog
import
domest
reservoir
etiolog
agent
human
viscer
leishmaniasi
reason
current
strategi
manag
diseas
man
includ
detect
elimin
seroposit
dog
alongsid
vector
control
therapi
individu
case
thu
past
year
brazilian
ministri
health
direct
screen
around
two
million
dog
elimin
seroposit
anim
incid
human
vl
reduc
accept
level
approach
entir
effect
howev
partli
resist
dog
owner
acquiesc
euthanasia
infect
pet
context
vaccin
vl
would
import
tool
control
cvl
would
also
dramat
decreas
infect
pressur
l
chagasi
human
although
effect
vaccin
human
vl
yet
avail
much
effort
expend
area
recent
year
sever
candid
vaccin
antigen
studi
extens
mice
howev
result
obtain
vaccin
vl
design
test
use
mous
model
necessarili
extrapol
speci
situat
wellillustr
refer
vaccin
develop
dunan
et
al
effect
murin
model
offer
protect
cvl
ideal
vaccin
design
protect
dog
develop
use
canin
model
recent
strategi
develop
vaccin
leishmaniasi
base
use
purifi
fraction
parasit
extract
flm
antigen
parasit
cultur
excretedsecret
antigen
encourag
result
report
howev
vaccin
prepar
whole
parasit
antigen
extract
still
remain
reliabl
perspect
consid
broad
spectrum
antigen
cost
safeti
number
vaccin
test
phase
ii
clinic
trial
mayrink
et
al
demonstr
enhanc
lymphocyt
prolifer
signific
protect
infect
leishmania
brazilian
dog
receiv
merthiol
ultrasounddisrupt
promastigot
l
braziliensi
togeth
bacillu
bcg
strong
cellular
prolifer
solubl
leishmania
antigen
sla
also
report
dog
vaccin
autoclav
l
major
promastigot
alm
plu
bcg
addit
vaccin
compos
l
infantum
promastigot
freezethaw
emulsifi
freund
complet
adjuv
induc
high
parasiticid
activ
increas
format
nitric
oxid
macrophag
treat
dog
moreov
singl
dose
vaccin
compos
aluminium
hydroxid
alum
precipit
l
major
alumalm
plu
bcg
shown
safe
decreas
incid
cvl
equival
efficaci
rate
consid
promis
result
obtain
use
leishmania
crude
antigen
vaccin
togeth
somewhat
simpler
facil
requir
manufactur
lower
product
cost
involv
kill
leishmania
crude
antigen
vaccin
could
use
control
cvl
endem
area
develop
countri
howev
studi
publish
detail
immun
statu
dog
follow
vaccin
evalu
probabl
owe
lack
specif
reagent
standardis
method
investig
canin
cell
biolog
present
paper
present
detail
analysi
immunogenicityantigen
cvl
vaccin
compos
l
braziliensi
antigen
plu
saponin
adjuv
detail
studi
present
approv
ethic
committe
use
experiment
anim
universidad
feder
de
mina
gerai
belo
horizontemg
brazil
promastigot
l
braziliensi
maintain
vitro
cultur
nnnlit
media
describ
previous
parasit
harvest
centrifug
g
min
c
cultur
wash
three
time
salin
buffer
fulli
disrupt
ultrasound
treatment
w
min
c
separ
aliquot
store
c
requir
use
protein
concentr
determin
accord
method
lowri
et
al
vaccin
describ
regist
instituto
nacion
da
propriedad
industri
brazil
patent
number
pi
februari
twentyf
male
femal
mongrel
dog
born
rear
kennel
instituto
de
exata
e
universidad
feder
de
ouro
preto
ouro
preto
mina
gerai
brazil
treat
month
anthelmint
vaccin
rabi
tecpar
curitibapr
brazil
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
vanguard
htlp
pfizer
anim
health
new
york
ny
usa
absenc
specif
antileishmania
antibodi
confirm
indirect
fluoresc
immunoassay
experiment
dog
treat
within
four
experiment
group
follow
control
group
c
n
receiv
ml
steril
salin
ii
lb
group
n
receiv
g
l
braziliensi
promastigot
protein
ml
steril
salin
iii
sap
group
n
receiv
mg
saponin
sigma
chemic
co
st
loui
mo
usa
ml
steril
salin
iv
lbsap
group
n
receiv
g
l
braziliensi
promastigot
protein
mg
saponin
ml
steril
salin
case
anim
receiv
three
subcutan
inject
right
flank
interv
week
dog
monitor
close
week
inject
gener
toler
vaccin
ascertain
overal
evalu
includ
rectal
temperatur
measur
health
anim
local
toler
determin
direct
visual
examin
lesion
observ
measur
h
interv
period
h
inject
anim
follow
complet
cours
studi
veterinarian
provid
full
medic
support
requir
peripher
blood
ml
collect
jugular
vein
dog
transfer
tube
contain
suffici
edta
produc
final
concentr
mgml
absolut
count
lymphocyt
sampl
obtain
use
coulter
miami
fl
usa
model
instrument
blood
sampl
store
room
temperatur
h
prior
process
immunogen
evalu
determin
antibodi
solubl
lysat
l
chagasi
antigen
slca
accord
convent
enzymelink
immunosorb
assay
elisa
describ
rei
et
al
slca
coat
onto
micropl
maxisorp
tm
nalg
nunc
intl
rochest
ny
usa
concentr
gwell
serum
sampl
ad
dilut
well
wash
peroxidaseconjug
goat
antidog
sheep
antidog
igg
bethyl
laboratori
inc
montgomeri
tx
usa
ad
dilut
respect
well
wash
substrat
chromogen
ophenylenediamin
sigmaaldrich
co
st
loui
mo
usa
ad
absorb
read
nm
multiskan
mcc
labsystem
helsinki
finland
automat
micropl
reader
unlabel
canin
monoclon
antibodi
mab
clone
clone
clone
use
indirect
immunofluoresc
procedur
pool
normal
rat
serum
dilut
employ
isotyp
control
fluorescein
isothiocyan
fitc
label
igg
sheep
antirat
polyclon
antibodi
use
secondari
antibodi
nonspecif
bind
secondstep
reagent
block
pool
normal
sheep
serum
phosphatebuff
salin
pb
contain
foetal
bovin
serum
gibco
grand
island
ny
usa
fitclabel
mous
clone
iobla
phycoerythrin
pe
mous
clone
rpeconjug
mous
antimous
mhci
clone
mab
use
direct
immunofluoresc
procedur
attempt
identifi
optim
dilut
assay
mab
previous
titr
solut
pb
contain
bovin
serum
albumin
sodium
azid
unlabel
mab
antimhci
mab
purchas
serotec
oxford
uk
immunotech
co
marsel
franc
micropl
assay
immunophenotyp
canin
whole
blood
leukocyt
wbl
fresh
blood
sampl
peripher
blood
mononuclear
cell
pbmc
obtain
vitro
stimul
carri
describ
rei
et
al
flowcytometr
measur
perform
facscan
instrument
becton
dickinson
moutain
view
ca
usa
interfac
appl
workstat
cellquest
softwar
becton
dickinson
use
data
acquisit
analysi
total
event
acquir
prepar
canin
wbl
select
basi
characterist
forward
fsc
side
ssc
lightscatt
distribut
follow
fsc
ssc
gain
adjust
lymphocyt
select
gate
fsc
versu
ssc
graph
fluoresc
evalu
fitc
spectra
singlehistogram
represent
monocyt
analys
fluoresc
intens
detect
singl
histogram
obtain
directli
ungat
leukocyt
data
analysi
marker
set
intern
control
nonspecif
bind
order
encompass
unlabel
cell
marker
use
data
analysi
given
anim
result
express
percentag
posit
cell
within
select
gate
cell
surfac
marker
present
bimod
distribut
semiquantit
analys
carri
cell
surfac
marker
mhci
exhibit
unimod
distribut
order
evalu
differenti
express
result
express
mean
fluoresc
channel
mfc
log
scale
data
also
express
absolut
count
order
allow
normal
valu
obtain
group
whose
overal
leukocyt
count
differ
absolut
count
lymphocyt
monocyt
calcul
global
leukocyt
count
percentag
lymphocyt
monocyt
hematoscopi
absolut
count
lymphocyt
subset
monocyt
calcul
absolut
lymphocyt
count
percentag
fluoresc
posit
cell
within
lymphog
global
leukocyt
count
percentag
fluoresc
posit
cell
within
ungat
monocyt
pbmc
isol
ml
sampl
heparinis
blood
layer
onto
ml
ficollhypaqu
densiti
gradient
histopaqu
sigma
chemic
co
centrifug
g
min
room
temperatur
separ
pbmc
resuspend
gibco
rpmi
medium
homogenis
wash
twice
rpmi
centrifug
g
min
room
temperatur
homogenis
final
resuspend
rpmi
cellsml
vitro
assay
cell
cultur
medium
compris
rpmi
supplement
streptomycin
mgml
penicillin
uml
lglutamin
mm
heatinactiv
foetal
calf
serum
lymphoprolifer
assay
perform
flatbottom
tissu
cultur
plate
corn
new
york
ny
usa
well
contain
l
supplement
rpmi
medium
aliquot
l
pbmc
cellswel
ad
triplic
well
togeth
l
vaccin
solubl
antigen
vsa
l
braziliensi
gml
l
slca
gml
obtain
accord
rei
et
al
antigen
stimulu
assay
mitogen
stimulu
assay
l
aliquot
pbmc
cellswel
ad
triplic
well
togeth
l
phytohaemagglutinin
pha
gml
sigmaaldrich
chemi
gmbh
taufkirchen
germani
incub
carri
humidifi
co
atmospher
c
day
mitogenicstimul
cultur
day
antigenicstimul
cultur
six
hour
prior
termin
cultur
ci
hthymidin
sigma
chemic
co
ad
well
cell
subsequ
harvest
onto
glass
fibr
filter
incorpor
radioact
determin
liquid
scintil
count
control
assay
prepar
exactli
employ
l
aliquot
pbmc
cellswel
l
rpmi
medium
replac
stimul
incub
appropri
time
prolifer
respons
express
term
mean
count
per
minut
triplic
well
whilst
stimul
index
calcul
mean
prolifer
respons
cultur
stimul
vsa
slcamean
prolifer
respons
unstimul
cultur
order
investig
immunophenotyp
featur
pbmc
cultur
flatbottom
tissu
cultur
plate
costar
cambridg
usa
well
contain
l
supplement
rpmi
medium
aliquot
l
pbmc
cellswel
ad
triplic
well
togeth
l
vsa
gml
l
slca
gml
control
assay
prepar
employ
l
aliquot
pbmc
cellswel
l
rpmi
medium
replac
stimul
incub
carri
humidifi
co
atmospher
c
day
pbmc
remov
immunophenotyp
supernat
collect
assay
describ
indirect
measur
product
vitro
nitrit
level
determin
supernat
pbmc
cultur
use
griess
reaction
briefli
l
aliquot
griess
reagent
naphthylethylenediamin
dihydrochlorid
sulphanylamid
phosphor
acid
sigma
chemic
co
ad
cultur
supernat
follow
min
incub
dark
room
temperatur
absorb
measur
nm
automat
micropl
reader
sampl
assay
duplic
concentr
nitrit
determin
interpol
standard
curv
construct
use
sodium
nitrit
solut
known
concentr
rang
moll
data
express
mean
product
index
antigenstimul
culturecontrol
cultur
order
compar
valu
cultur
supernat
prepar
immedi
prior
applic
first
dose
vaccin
day
applic
third
dose
vaccin
statist
analys
perform
use
prism
softwar
packag
prism
softwar
irvin
ca
usa
normal
data
demonstr
use
kolmogorovsmirnoff
test
oneway
analysi
varianc
anova
tukey
posttest
use
determin
differ
group
term
humor
immun
respons
immunophenotyp
profil
student
ttest
use
evalu
differ
mean
valu
determin
vitro
assay
stimul
cultur
control
cultur
prepar
pearson
rank
correl
employ
investig
associ
phenotyp
featur
circul
leukocyt
phenotyp
featur
cell
prolifer
case
differ
consid
signific
p
valu
vaccin
associ
hyperthermia
pain
fever
lymphadenopathi
gener
advers
reaction
moreov
local
advers
reaction
observ
vaccin
dog
except
mild
local
indur
reaction
dog
vaccin
prepar
contain
saponin
tabl
nodul
commonli
observ
second
inject
vaccin
result
format
ulcer
lesion
tabl
local
alter
inoculum
region
measur
h
saponin
l
braziliensi
vaccin
saponin
inocul
anim
code
nodul
size
cm
antibodi
leishmania
associ
signifi
mix
immun
respons
signific
p
increas
serum
level
antileishmania
total
igg
day
applic
second
dose
vaccin
observ
dog
lbsap
group
compar
sap
lb
control
c
group
fig
upper
left
panel
analysi
demonstr
level
antileishmania
fig
upper
right
panel
fig
lower
left
panel
enhanc
p
lbsap
group
compar
group
moreov
posit
associ
level
fig
lower
right
panel
preliminari
compar
analysi
cell
profil
treatment
group
show
day
applic
first
dose
vaccin
sig
nific
p
reduct
number
circul
lymphocyt
sap
lb
group
compar
control
group
c
fig
upper
panel
detail
investig
immunophenotyp
featur
lymphocyt
fig
middl
panel
reveal
increas
p
number
circul
tlymphocyt
lbsap
group
compar
sap
group
significantli
p
higher
count
tcell
subset
bcell
lbsap
group
compar
sap
control
c
group
furthermor
absolut
count
obtain
possibl
demonstr
posit
correl
within
lbsap
group
respect
tcell
versu
bcell
p
r
versu
tcell
p
r
fig
middl
panel
respect
p
r
p
r
versu
tcell
fig
lower
panel
vitro
cell
reactiv
determin
presenc
vsa
order
evalu
memori
lymphoprolif
immun
respons
presenc
slca
order
investig
possibl
lymphoprolif
homolog
complet
antigen
repertoir
etiolog
agent
vl
fig
upper
panel
lymphoprolif
activ
compar
lb
group
reduc
p
presenc
either
stimulu
contrast
lbsap
group
display
signific
p
increas
stimul
index
compar
presenc
stimuli
addit
valu
record
presenc
vsa
significantli
p
higher
observ
lb
sap
control
c
group
analysi
lymphoprolif
immun
respons
presenc
slca
also
demonstr
signific
increas
p
comparison
observ
lb
group
nonspecif
lymphoprolif
respons
evalu
stimul
index
si
pha
mitogeninduc
cell
prolifer
data
confirm
high
degre
cell
viabil
demonstr
outstand
si
valu
observ
mitogenicstimul
cultur
rang
mean
valu
data
shown
vitro
immunophenotyp
profil
evalu
presenc
absenc
vsa
slca
presenc
vsa
fig
left
middl
lower
panel
sig
result
express
mean
frequenc
cell
nonstimul
cultur
cc
control
stimul
cultur
sc
signific
differ
p
valu
measur
first
dose
day
third
dose
indic
connect
line
lbsap
control
c
sap
lb
group
repres
letter
b
c
respect
nificantli
p
reduc
frequenc
bcell
observ
sap
lb
group
compar
nonstimul
control
cultur
moreov
follow
stimul
vsa
lbsap
group
exhibit
higher
p
frequenc
blymphocyt
compar
lb
group
similar
result
obtain
vitro
cultur
stimul
slca
fig
right
middl
lower
panel
indic
frequenc
bcell
decreas
p
sap
group
compar
control
cultur
increas
p
lbsap
group
compar
lb
group
moreov
although
differ
observ
frequenc
tcell
assay
involv
vsa
stimul
cultur
stimul
slca
lb
group
exhibit
higher
frequenc
tcell
compar
control
c
group
mainli
due
increas
p
level
tcell
addit
compar
lb
group
lbsap
group
present
lower
p
level
tcell
increas
p
frequenc
tcell
search
potenti
antigenpres
cell
apc
anim
vaccin
lbsap
observ
number
circul
monocyt
higher
p
group
dog
sap
group
lb
sap
group
fig
upper
left
panel
analysi
data
relat
statu
lymphocyt
activ
demonstr
differenti
express
mhci
lbsap
group
lead
significantli
p
increas
mean
fluoresc
channel
mfc
gate
lymphocyt
compar
lb
sap
control
c
group
lb
group
fig
upper
middl
panel
investig
reveal
posit
associ
lymphocyt
activ
statu
mhci
level
circul
monocyt
p
r
highlight
connect
event
vaccin
immunis
fig
upper
right
panel
order
identifi
apc
impart
major
contribut
specif
vitro
antigen
stimul
correl
analys
perform
use
data
deriv
lbsap
group
fig
middl
panel
result
demonstr
posit
associ
monocyt
vitro
cell
prolifer
cultur
stimul
vsa
p
r
neg
correl
cultur
stimul
slca
p
r
contrast
bcell
count
exhibit
neg
associ
cell
prolifer
vsastimul
cultur
p
r
posit
associ
cultur
stimul
slca
p
r
data
provid
evid
distinct
apc
accord
antigen
stimulu
suggest
monocyt
might
act
apc
vaccin
antigen
stimul
whilst
bcell
could
fulfil
role
slca
stimul
sinc
product
consid
key
element
kill
mechan
mediat
elimin
intracellular
pathogen
level
antimicrobi
oxid
produc
vitro
antigenicstimul
pbmc
deriv
dog
vaccin
lbsap
determin
interestingli
higher
p
level
reactiv
radic
nitrit
record
supernat
slcastimul
cultur
compar
fig
lower
panel
suggest
outcom
relat
immun
respons
attempt
determin
whether
immunophenotyp
featur
vitro
pbmc
cultur
subject
antigen
stimul
associ
specif
cell
profil
analys
level
associ
cell
type
prolifer
within
four
group
fig
data
analysi
demonstr
posit
associ
lbsap
group
specif
tcell
cell
reactiv
vsaand
slcastimul
cultur
canin
viscer
leishmaniasi
resembl
human
viscer
leishmaniasi
respect
mani
symptom
sever
chronic
diseas
often
fatal
natur
histori
cvl
well
describ
particularli
regard
parasit
load
differ
tissu
immunopatholog
chang
accord
progress
clinic
form
data
provid
support
improv
tool
employ
evalu
chemotherapi
vaccin
develop
cvl
unfortun
differ
treatment
strategi
fail
achiev
consist
parasitolog
cure
cvl
owe
presenc
latent
infect
cell
context
dog
vaccin
may
practic
effect
method
reduc
incid
human
vl
might
also
permit
similar
vaccin
develop
human
featur
point
immunoprophylaxi
promis
altern
prevent
cvl
reason
consider
effort
dedic
studi
immun
respons
cvl
sever
leishmania
antigen
implic
respons
report
major
consensu
l
chagasiinfantum
antigen
display
potent
immunosuppress
potenti
would
deleteri
immunoprotect
cvl
sever
studi
report
potenti
l
chagasi
antigen
trigger
immunosuppress
block
vitro
lymphoprolif
respons
leishmania
antigen
well
synthesi
proinflammatori
cytokin
antigenpres
cell
use
purifi
leishmania
donovani
l
infantum
antigen
also
propos
overcom
immunosuppress
effect
l
chagasi
antigen
studi
includ
clinic
trial
vaccin
candid
cvl
immunoprofilaxi
conduc
use
either
l
amazonensi
l
braziliensi
l
major
antigen
previou
studi
group
demonstr
l
braziliensi
antigen
potent
role
protect
l
chagasi
infect
dog
unpublish
data
therefor
critic
question
screen
develop
antileishmani
vaccin
cvl
defin
leishmania
antigen
adjuv
system
elicit
favor
sustain
cytokin
environ
vivo
consid
import
immunoprofilaxi
strategi
control
leishmaniasi
lack
studi
concern
cellular
humor
event
occur
vaccin
attempt
evalu
immun
respons
promis
new
vaccin
candid
cvl
compos
l
braziliensi
antigen
plu
saponin
adjuv
assess
inform
essenti
prerequisit
understand
mechan
relat
immunogen
elicit
candid
vaccin
result
obtain
indic
dog
exhibit
local
swell
reaction
ulcer
lesion
advers
reaction
receiv
saponin
adjuv
although
overal
toler
candid
vaccin
dog
appear
adequ
import
mention
frequenc
andor
size
local
reaction
suffici
safeti
standard
veterinari
vaccin
therefor
studi
still
requir
overcom
issu
search
addit
safeti
biomark
use
saponin
vaccin
adjuv
side
effect
report
follow
use
saponin
adjuv
includ
nonspecif
immun
reaction
loss
hair
site
inject
anorexia
apathi
vomit
diarrhoea
howev
saponin
induc
develop
strong
tlymphocyt
cytotox
use
adjuv
includ
sever
veterinari
vaccin
present
studi
evalu
immunogen
lb
lbsap
reveal
anim
treat
lb
togeth
saponin
adjuv
present
higher
p
amount
antileishmania
total
igg
associ
increas
p
level
sinc
respons
strictli
tcell
depend
previous
employ
measur
overal
immunogen
recombin
antigen
dog
furthermor
subtyp
tradit
use
surrog
phenotyp
immun
respons
mice
wherea
respons
gener
relat
respons
human
howev
associ
igg
subtyp
immun
respons
term
phenotyp
straightforward
dog
find
immunoglobulin
isotyp
suggest
mix
immun
respons
trigger
lbsap
vaccin
intens
humor
immun
respons
demonstr
lbsap
group
synchron
increas
p
count
circul
bcell
follow
first
immunis
result
differenti
plasmacyt
higher
level
immunoglobulin
secret
addit
higher
number
p
circul
tcell
lbsap
group
posit
correl
bcell
suggest
possibl
cooper
tand
bcell
immunis
sequenc
protect
infect
leishmania
reli
cellmedi
immun
respons
impli
success
immunis
protocol
abl
activ
cellmedi
immun
immunis
anim
present
studi
increas
tcell
lbsap
group
associ
increas
level
tcell
moreov
posit
correl
tcell
tcell
subset
tcell
suggest
signific
cooper
cellular
level
observ
earli
clonal
expans
gener
primari
cytotox
effector
addit
augment
circul
tcell
ongo
cvl
previous
describ
major
phenotyp
featur
asymptomat
diseas
dog
bear
low
parasit
load
thu
find
support
hypothesi
tlymphocyt
play
role
protect
immun
leishmania
infect
suggest
previous
cvl
order
evalu
activ
statu
lymphocyt
immunis
protocol
express
mhci
studi
find
higher
express
mhci
lymphocyt
lbsap
group
indic
improv
activ
statu
lymphocyt
immunis
protocol
propos
increas
express
mhcii
may
reflect
antigen
primingrel
immunolog
event
consist
hypothesi
demonstr
dog
asymptomat
cvl
display
enhanc
activ
statu
circul
lymphocyt
determin
mhcii
togeth
lower
overal
tissu
parasit
howev
data
present
studi
highlight
import
mhci
express
activ
marker
lymphocyt
fact
upregul
mhci
ii
relat
presenc
consist
hypothesi
evalu
apc
reveal
increas
number
circul
monocyt
lbsap
group
associ
increas
mhci
express
lymphocyt
basi
result
possibl
specul
associ
would
repres
interact
innat
adapt
immun
respons
reflect
improv
activ
statu
lbsap
immunis
aim
determin
whether
candid
vaccin
would
activ
pbmc
vitro
antigen
stimul
measur
stimul
index
cell
deriv
lbsap
lb
dog
higher
cell
reactiv
follow
stimul
either
vsa
slca
record
lbsap
group
third
immunis
wherea
stimul
index
lb
group
lower
compar
thu
find
support
hypothesi
pbmc
prolifer
lbsap
group
associ
recognit
l
chagasi
antigen
suggest
vaccin
may
valu
etiolog
agent
vl
analys
carri
order
investig
profil
apc
vitro
cultur
pbmc
lbsap
group
subject
antigen
stimuli
whilst
cell
prolifer
exhibit
posit
associ
circul
monocyt
presenc
vsa
neg
correl
observ
upon
slca
stimul
contrast
neg
associ
bcell
cell
prolifer
observ
presenc
vsa
posit
associ
upon
slca
stimul
find
indic
distinct
profil
apc
cultur
establish
monocyt
bcell
major
apc
respect
vitro
stimul
vsa
slca
vitro
cultur
pbmc
deriv
lbsap
group
stimul
vsa
slca
increas
lymphoprolifer
activ
accompani
higher
frequenc
bcell
demonstr
potenti
immunoglobulin
isotyp
produc
contrast
differ
observ
frequenc
tcell
follow
vitro
stimul
whilst
reduct
frequenc
tcell
increas
level
tcell
associ
slca
stimulu
result
support
hypothesi
tcell
play
protect
role
mechan
control
leishmania
parasit
addit
correl
analysi
reveal
tcell
exhibit
posit
associ
cell
prolifer
vitro
follow
stimul
vsa
slca
data
suggest
possibl
stimul
antigenspecif
tcell
subset
follow
lbsap
immunis
could
contribut
improv
cellular
immun
respons
l
chagasi
infect
result
obtain
analysi
level
determin
nitrit
cultur
supernat
confirm
hypothesi
lbsap
immunis
induc
potenti
resist
profil
leishmania
infect
despit
higher
nitrit
level
observ
vitro
cell
stimul
slca
conclus
result
present
studi
provid
support
continu
develop
vaccin
base
whole
parasit
approach
strategi
vaccin
design
attract
term
safeti
stabil
product
compar
purifi
subunit
prepar
dna
vaccin
involv
sophist
technolog
may
readili
avail
develop
countri
furthermor
contrast
recombin
vaccin
kill
vaccin
requir
fewer
test
carri
bulk
intermedi
finish
product
make
cost
product
lower
recombin
protein
addit
kill
vaccin
present
great
divers
antigen
repertoir
potenti
activ
stronger
cellular
respons
mainli
tlymphocyt
compar
purifi
subunit
prepar
dna
vaccin
major
find
present
studi
point
strong
antigen
candid
vaccin
relat
increas
immunoglobulin
isotyp
togeth
higher
level
lymphocyt
particularli
circul
tlymphocyt
slcaspecif
tlymphocyt
addit
intens
cell
prolifer
product
vitro
stimul
slca
show
lbsap
vaccin
elicit
potenti
immun
activ
statu
potenti
compat
effect
control
etiolog
agent
cvl
investig
focu
efficaci
lbsap
vaccin
protect
experiment
challeng
l
chagasi
